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Abstract
Background: Live vaccines have distinct safety profiles, potentially causing systemic reactions one to 2 weeks after
administration. In the province of Ontario, Canada, live MMR vaccine is currently recommended at age 12 months and 18
months.
Methods: Using the self-controlled case series design we examined 271,495 12 month vaccinations and 184,312 18 month
vaccinations to examine the relative incidence of the composite endpoint of emergency room visits or hospital admissions
in consecutive one day intervals following vaccination. These were compared to a control period 20 to 28 days later. In a
post-hoc analysis we examined the reasons for emergency room visits and the average acuity score at presentation for
children during the at-risk period following the 12 month vaccine.
Results: Four to 12 days post 12 month vaccination, children had a 1.33 (1.29–1.38) increased relative incidence of the
combined endpoint compared to the control period, or at least one event during the risk interval for every 168 children
vaccinated. Ten to 12 days post 18 month vaccination, the relative incidence was 1.25 (95%, 1.17–1.33) which represented at
least one excess event for every 730 children vaccinated. The primary reason for increased events was statistically significant
elevations in emergency room visits following all vaccinations. There were non-significant increases in hospital admissions.
There were an additional 20 febrile seizures for every 100,000 vaccinated at 12 months.
Conclusions: There are significantly elevated risks of primarily emergency room visits approximately one to two weeks
following 12 and 18 month vaccination. Future studies should examine whether these events could be predicted or
prevented.
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Introduction
The measles, mumps and rubella (MMR) have been used
extensively in children and have been demonstrated to be safe and
effective in preventing disease [1]. However, because it is a live
vaccine the MMR vaccine has the potential to cause adverse events
one to 2 weeks following vaccination [2]. Most reactions to this
v a c c i n ew i l lb em i l dw i t hf e v e r so c c u r r i n gi n5t o1 5 %a n dr a s h e si n
5% [3]. More serious reactions are extremely rare and may not be
identified during pre-licensure trials [4]. Post market surveillance has
identified an incidence of febrile seizures following the MMR vaccine
of 25 to 34 per 100 000 vaccinated and a two to three-fold increased
relative risk [5,6]. However, at a population level, mass exposures to a
v a c c i n ew i t har a r es i d ee f f e c tp r o f i l ec o u l dh a v ed e t e c t a b l ei m p o r t a n t
population level effects. No study has examined the impact on
aggregate health service utilization following the MMR vaccination.
In the province of Ontario, Canada, the MMR and meningococ-
cal C vaccines are currently recommended at 12 months of age and a
second dose of MMR vaccine along with a booster dose of
pentavalent (diphtheria, acellular pertussis, tetanus, polio and
Haemophilus influenzae type b) vaccine is recommended at 18 months
of age. We sought to examine the population wide effects of these
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27897vaccinations on the combined endpoint of emergency room visits and
hospital admissions in selected periods post-vaccination.
Methods
Design
The overall goal of this study was to determine the risk of
serious adverse events in all children vaccinated in Ontario at 12
and 18 months of age with recommended pediatric vaccines. This
was measured by comparing the risk of either presentation to
emergency room (ER), or hospital admission in consecutive one
day periods after the date of vaccination compared to a later
control period. This analysis was conducted on all children born
between April 1
st 2006 and March 31
st 2009. Our primary analysis
of the composite risk of ER visits and hospitalizations was
conducted using the self-controlled case-series design, described by
Figure 1. Illustration of the self-controlled case series design. The observation period for each patient begins with pediatric vaccination date
(leftmost upward arrow) and continues for a total of 28 days. In the primary analyses, each day post vaccination is considered a risk interval, and
consecutive days with a statistically significant t elevation in relative incidence were pooled to create a combined risk interval. Days 20–28 comprise
the control interval. The intervening days represent the wash-out period.
doi:10.1371/journal.pone.0027897.g001
Figure 2. Vaccination events by days since birth from days 340 to 700. Count=number of individuals vaccinated on a given day.
Days=number of days after date of birth.
doi:10.1371/journal.pone.0027897.g002
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12 and 18 month vaccinations separately.
Data
Our study cohort included all children in the Newborn
Screening Ontario data set between April 1
st 2006 and March
31
st 2009. This database captures over 99% of Ontario births. Our
exposure of interest, pediatric vaccination, was identified using the
Ontario Health Insurance Plan (OHIP) database. We used codes
for general vaccination, as, except for influenza, vaccine-specific
codes are not available. To identify the 12 and 18 month
vaccinations separately we identified vaccination occurring on
exactly the respective due dates as well as vaccinations occurring
up to 60 days after the respective date. To allow adequate follow-
up after the 12 month vaccination, only vaccinated children born
on or before December 31
st 2008 could be included in the analysis
(N=271,495 children). Likewise, only vaccinated children born on
or before June 30
th 2008 could be included in the analysis of
adverse events after the 18 month vaccination (N=184,312
children). Only subjects with both vaccinations and events in the
observation period contribute to the conditional self-controlled
case series analysis, therefore infants with no ER visits or
hospitalizations in close proximity to the vaccination were not
included. If infants had more than one vaccination in the database
during the two month target period the first vaccination was used
as the index vaccination. If another vaccination occurred within
the observation period (0 to 28 days after the index vaccination), or
the infant died, then this individual was excluded from analysis (see
Appendix S1).
The Canadian Institute for Health Information’s (CIHI)
Discharge Abstract Database (DAD) captures all hospital admis-
sions, including children in both tertiary and community hospitals,
and was used to ascertain hospital admission. CIHI’s National
Ambulatory Care Registration System (NACRS) was used to
ascertain ER visits, the Canadian Triage and Acuity Score (CTAS)
rating and the diagnosis made by the most responsible physician
for the visit. The Registered Persons Database was used to
ascertain cases of death. These datasets are housed at the Institute
for Clinical Evaluative Sciences (ICES), and linkage between
datasets was achieved using encrypted health card numbers as
unique identifiers. The study was performed within ICES’ status as
a Prescribed Entity in Ontario’s privacy legislation and Research
Ethics Board approval was received at OHRI and ICES
(Sunnybrook).
Analysis
We graphed the number of combined endpoint events in the
days before and after vaccination. In the self-controlled case series
model, the date of vaccination serves as the index date for
exposure for each patient. Previous studies have identified that
children are at increased risk for systemic reactions at different
times from 5–14 days after vaccination [5,6,9,10]. Because a priori
we did not know with certainty the time period following
vaccination for which there would be an increased risk of our
combined endpoint, we modified the standard self-controlled case
series approach by looking for an elevation in risk during each
post-vaccination day up to day 17 (Figure 1). We then classified
days 20–28 as unexposed, establishing a washout period in
Figure 3. Number of combined endpoints versus days before/after 12 month vaccination. Count=number of combined endpoints of
emergency room visit or hospitalization. Days=number of days before or after vaccination, day 0 being the day of vaccination.
doi:10.1371/journal.pone.0027897.g003
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multiple events occurred to a given individual, the first occurrence
of the composite outcome in the post-vaccination period was used
(eg., someone attending the ER who was then admitted would
have one event counted in that period). The relative incidence rate
of the composite endpoint during the exposed period compared
with the unexposed period was analyzed using a fixed effects
Poisson regression model. This model included a term for
exposure period and a term for patient, thereby allowing each
individual to serve as his or her own control and accounting for
intra-individual correlation. An offset term was also included to
account for the differing durations of the exposed and unexposed
periods. Deaths after the 12 and 18 month vaccinations were
explored in a separate analysis due to the fact that a subject dying
effectively truncates their follow-up potentially biasing the results
of the SCCS analysis. As noted above, children who died during
the follow-up period were excluded from the SCCS analysis of ER
visits and hospitalizations.
To define the at-risk period we combined consecutive days with
statistically significant elevations in relative incidence. We
considered statistical significance to be a p-value less than or
equal to 0.001 based on a Bonferroni correction to account for
multiple testing (38 separate tests) [11]. We conducted separate
analyses for the 12 and 18 month vaccinations. We also conducted
secondary analyses to determine the association between vaccina-
tion and ER visits, hospital admissions, and deaths separately. All
p values were 2 sided, and analyses were conducted using SAS
version 9.2 (SAS Institute, Cary, NC).
In order to assess the types of cases captured by our endpoints
we conducted a post-hoc analysis where we compiled the reasons
for presentation to the ER as determined by the most responsible
physician for the risk period for the 12 month vaccination. This
was compared to the prevalence of the same diagnoses in the
control period. We examined a tracer condition, ear/face nose
injury, for which we do not expect a difference in rates. We also
identified the CTAS ratings for presentations during the affected
period and compared them to those during the control period
using the Wilcoxon Rank-Sum test. CTAS ratings range from 1 to
5 with 1 representing a severe condition requiring resuscitation
and 5 representing a less severe condition requiring non-urgent
care [12]. In another post-hoc analysis we graphically examined
the pattern of events following 12 and 18 month vaccination in the
years 2002–2005 when the MMR vaccine was still given at 12
months, however, the booster was given at five years and not
eighteen months.
Results
In total, we examined 455,807 separate vaccination events in
these 413,957 children that occurred at 12 and 18 months plus 60
days (Figure 2). We present the number of endpoint events versus
days pre and post vaccination graphically for each of the vaccine
periods (Figures 3 and 4).
12 month analysis
271,495 children received vaccinations between 365 and 425
days of age. Consecutive statistically significant elevations in
combined endpoints began on day 4 and continued to day 12. A
Figure 4. Number of combined endpoints versus days before/after 18 month vaccination. Count=number of combined endpoints of
emergency room visit or hospitalization. Days=number of days before or after vaccination, day 0 being the day of vaccination.
doi:10.1371/journal.pone.0027897.g004
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endpoints during the combined 9 day at risk period compared to
4845 during the 9 day control period. The relative incidence of the
combined endpoint was 1.33 (1.29–1.38) (Table 1). The highest
relative incidence during the at-risk period occurred between days
8 and 11 peaking at 2.04 (1.91–2.17) on day 9. Overall, an excess
of 595 children experienced at least one of the combined
endpoints during the risk interval per 100,000 vaccinated, or
one additional child experiencing at least one endpoint during the
risk interval for every 168 children who received their 12 month
vaccinations (Table 2). Examining the historical graph of the
events post 12 month vaccination in the years 2002–2005
demonstrated a similar peak in events (Figure 5).
The primary reason for the elevation in the combined endpoint
was an increase in ER visits (relative incidence 1.34(1.29–1.39)).
There were an excess of 598 children experiencing 1 or more ER
visits during the risk interval per 100,000 vaccinations or 1
additional child for every 168 children vaccinated. There was no
increase in hospital admissions (relative incidence 1.08 (0.93–
1.25)). There were five or fewer deaths (Table 3). The average
CTAS score for ER visits during the risk period was 3.27
compared to 3.26 for the control period. (p=0.74), suggesting no
differences in severity of presentation between ER visits in the risk
and control periods. There was an increase in presentation for
multiple conditions during the risk period compared to the control
period. The largest relative risk was associated with febrile seizures
(relative incidence=2.34, fever (RI=2.31) and viral exanthem
(RI=2.23). We calculated that there were approximately 20
additional febrile seizures during the risk interval for every
100 000 children vaccinated. There was no increase in our tracer
condition (ear/face/nose injury).
18 month analysis
184,312 children received vaccinations between 545 and 605
days of age. Consecutive statistically significant elevations in
combined endpoints began on day 10 and continued to day 12. A
total of 1275 children experienced at least one event included in
the combined endpoint during the combined three day at risk
period compared to 3065 during the nine day control period. The
relative incidence of the combined endpoint was 1.25 (1.17–1.33)
(Table 4). The highest relative incidence during the at-risk period
was 1.34 (1.21–1.47) which occurred on day 12. Overall, an
additional 137 children experienced at least one combined
endpoint during the three day risk period per 100,000 vaccinated,
or one additional child experiencing at least one excess event for
every 730 children vaccinated (Table 3). Examining the historical
graph of the events post 18 month vaccination in the years 2002–
2005, when the booster dose of the MMR vaccine was not given,
demonstrated no similar peak in events (Figure 5).
The primary reason for the elevation in the combined endpoint
was an increase in ER visits (relative incidence 1.25(1.18–1.34)).
There were an excess of 139 children experiencing one or more
ER visits during the risk interval or one excess visit for every 719
children vaccinated. There was not a significant increase in
hospital admissions (relative incidence 1.23(0.94–1.59)) (Table 4).
No deaths occurred in the risk or control periods.
Discussion
Our analysis demonstrated that the 12 and 18 month
vaccinations are not associated with an increase in adverse events
immediately following vaccination. Instead it showed a reduced
risk in this period, which is likely a result of the previously
Table 1. Relative incidence of combined endpoint (hospital admission or emergency room visit) following 12 month vaccination.
Risk interval* Endpoints during risk interval (n) Relative Incidence (95% CI) P value
Day 4 621 1.15 (1.06–1.25) 0.0008
Day 5 641 1.19 (1.10–1.29) ,0.0001
Day 6 647 1.20 (1.11–1.31) ,0.0001
Day 7 644 1.20 (1.10–1.30) ,0.0001
Day 8 870 1.62 (1.50–1.74) ,0.0001
Day 9 1096 2.04 (1.91–2.17) ,0.0001
Day 10 991 1.84 (1.72–1.97) ,0.0001
Day 11 923 1.72 (1.60–1.84)) ,0.0001
Day 12 713 1.32 (1.22–1.43) ,0.0001
Days 4 to 12** (Combined risk interval) 6462 1.33(1.29–1.38) ,0.0001
Days 20–28 (Control Interval) 4845 NA NA
*Risk and control intervals expressed as days following vaccination.
**Total number of endpoints in the combined risk interval are less than the cumulative individual day event total because some children may have experienced events
in multiple days and only the first event is counted.
doi:10.1371/journal.pone.0027897.t001
Table 2. Increased risk of combined endpoints from vaccination.
Vaccination
Additional children experiencing at least one event
(per 100,000 vaccinations) Number vaccinated Number vaccinated per excess event
12 months 595 271,495 168
18 months 137 184,312 730
doi:10.1371/journal.pone.0027897.t002
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increase in events occurring between 4 and 12 days post-
vaccination for the 12 month and, to a lesser extent and for a
shorter time period for the 18 month vaccines. The majority of
these events represented ER visits and at their peak, on day 9
following the 12 month vaccine, were approximately twice the
baseline rate. Although there was an increase in hospital admission
in each period, none of these increases were statistically significant.
Overall the increase in event rate following the 12 month vaccines
accounted for approximately 598 extra children experiencing one
or more ER visits during the risk interval per 100,000
vaccinations. The average acuity of patients presenting to the
emergency room was similar to that in the control period. The
conditions for which there were the largest increase in risk for
presentation to the emergency room during the risk interval
compared to the control interval following the 12 month vaccine
were febrile convulsions, fever and viral exanthema, consistent
with the known adverse event profile of MMR and varicella
vaccines. There were 20 additional febrile seizures for every
100,000 children vaccinated at 12 months.
The development of an inflammatory response approximately
one week after vaccination is recognized in the literature. For
example, the Centres for Disease Control and Prevention list days
7 to 12 post vaccination as the highest risk period for developing
fever and possibly a rash [15]. This closely coincides with our
observation of the time period during which emergency room
visits peaked. A previous twin study also identified the develop-
ment of systemic symptoms between days 6 and 14 and peaking on
day 10 [9]. A study of febrile seizures following MMR vaccination
identified the highest at risk period to be 8 to 14 days following
vaccination and a relative risk of 2.83 and other studies have made
similar observations [5,6,16]. These are consistent with our
findings. While it is known that vaccines can produce these
adverse events, our study demonstrated the population wide
impact of this effect and that these events are resulting in an
increase in health services utilization. The estimated 595
additional children experiencing at least one event for every
100 000 vaccinated translates into approximately one child
experiencing at least one event per 168 children vaccinated. The
explanation for this effect is likely the controlled replication of the
virus creating a mild form of the illness the vaccine is designed to
prevent. The top diagnoses for the presentations to the emergency
room during the 12 month risk interval would all be consistent
with a mild viral illness.
The reduced effect at 18 months is likely due to this vaccination
in most instances being a second exposure to the antigen to which
the vast majority of children would have developed adequate
immunity. Residual events during this period may represent the
small percentage of children who did not immunologically respond
to the first dose of the vaccine.
Our study has several strengths. The use of the self-controlled
case series design allows for individuals to serve as their own
controls implicitly controlling for all fixed covariates [8,17].
Seasonal confounding is unlikely to have influenced our findings
since the 12 and 18
th month vaccines are provided throughout the
year. The potential for confounding due to co-existent exposures
at 12 and 18 months exists, however, if such an exposure were to
be significant we would have expected to observe an effect at 18
months in our historical analysis. Our study included nearly all
children born in Ontario during the study period which
strengthens the generalizability of these findings. The combination
of the self-controlled case series design and our sample size
increased the power of our study to identify small effects. While
our study cannot establish causality it has many features that
support a causal relationship between vaccination and delayed
adverse events. These include the consistency with other studies
and a compelling biological model which explains the diagnoses in
the affected children and the reduction in effect with the 18 month
vaccinations. Furthermore, our historical analysis demonstrates
that the effect seen at 18 months after MMR vaccination in 2006–
2009 is not present in 2002–2005, when the MMR vaccine was
given only at 12 months and not at 18 months. The effect is still
clearly visible after the 12 month vaccination in the 2002–2005
data.
There are important limitations of this study. The first is that, as
mentioned, the healthy vacinee effect may have masked an
association in the immediate post-vaccination period. Second, we
cannot know whether a specific vaccine was associated with the
adverse events as multiple vaccines are typically administered at
each visit. However, we have previously demonstrated the safety of
the pentavalent vaccine which is given with the 18 month MMR
vaccine [18]. It is possible that the effects seen at 12 month are in
part due to the potential co-administration of the meningococcal C
vaccine, however, this is not a live vaccine and should create
inflammation in the immediate post-vaccination period as opposed
to one week later. Third, the codes we used for identifying the
reasons for presentation to the emergency room have not been
validated. However, we would expect that the diagnoses of febrile
convulsion to have a low misclassification error and has previously
been validated as a useful ER code in a separate dataset [19]. We
also did not look for increases in visits to physician offices that did
not result in presentation to the emergency room or admission and
cannot comment on the impact of immunization on that outcome.
Table 3. Relative incidences of individual endpoints (emergency room visit, hospital admission, death) during highest risk interval
compared to control period.
Outcome 12 months Events (risk/control) 18 months Events (risk/control)
Emergency visits 1.34 (1.29–1.39) 6395/4772 1.25 (1.18–1.34) 1264/3024
Admissions 1.08 (0.93–1.25) 356/330 1.23 (0.94–1.59) 78/191
Deaths - ,=5/,=5 - 0/0
doi:10.1371/journal.pone.0027897.t003
Figure 5. Historical analysis of combined endpoints versus days following 12 and 18 month vaccination: April 2002–March 2005. a)
Before/after 12 month vaccination. b) Before/after 18 month vaccination. Count=number of combined endpoints of emergency room visit or
hospitalization. Days=number of days before or after vaccination, day 0 being the day of vaccination.
doi:10.1371/journal.pone.0027897.g005
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care to children. The immediate risk of a serious adverse event
following immunization is low with both the vaccination visits that
contain the MMR and varicella vaccines. However, the 12 month
vaccines which typically contain the first dose of the MMR vaccine
is associated with an increased risk of an emergency room visit
approximately 4 to 12 days after immunization, peaking between
days 8 and 11. This increase in rate of a child experiencing at least
one event for every 158 vaccinated individuals is associated with a
similar acuity as the control period. If the presentation to the
emergency room was due to parental anxiety we would have
expected to see a reduction in acuity during the risk period. The
findings also suggest that the reactions are not severe since acuity
was not higher than the control period and furthermore, there
were few hospital admissions. Additional reassurance can be
derived from previous studies that identified no long-term
consequences related to vaccine associated febrile seizures [5,6].
The increase in ER visits we observed could be a result of
insufficient information being provided to parents who may not
expect their child to develop a reaction a week after vaccination.
In particular, the likelihood of this risk may be underestimated by
physicians. Our study also reinforces the reduced risk of events
following the second dose of MMR vaccine.
Given the effectiveness of the MMR vaccine in eliminating both
measles and rubella, and the highly infectious nature of these
diseases, high vaccination coverage is essential. The diseases that
the vaccines are preventing are not benign and vaccination can
eliminate many of the serious sequelae of these infections [20].
Complications from measles include otitis media (7–9% of cases),
pneumonia (1–6% of cases), encephalitis (1 per 1,000–2,000 cases),
subacute sclerosing panecephalitis (1 per 100,000 cases), and death
(1 per 3000 cases) [3,21]. Further studies attempting to predict
which children develop post-vaccination reactions, as well as
determining the effectiveness of prophylactic treatment with
antipyrectics prior to the high risk period for symptom
development are warranted.
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